PMVP ▼ -9.2% - PMV Pharmaceuticals, Inc.
$PMVP - PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors
20-NOV-2026 10:30 AM ET
Share this post
More filings for $PMVP
PMVP - PMV Pharmaceuticals, Inc. - SEC Filing Update (16-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 16, 2026PMVP ▲ +0.8% - PMV Pharmaceuticals, Inc.Nov 10, 2026PMVP ▲ +0.6% - PMV Pharmaceuticals, Inc.Oct 5, 2026PMVP - PMV Pharmaceuticals, Inc. - SEC Filing Update (15-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 15, 2026PMVP ▼ -1.6% - PMV Pharmaceuticals, Inc.Sep 8, 2026PMVP ▼ -2.5% - PMV Pharmaceuticals, Inc.Sep 1, 2026
View full $PMVP filing history →💬 Comments
Loading comments…
Leave a comment
